Print this page    •   Back to Web version of article

New Warning of Serious Intelence Side Effect

February 2010

In August 2009, the FDA announced an updated side effect warning for Intelence (etravirine), the newest approved NNRTI. This comes after reports of severe allergic reactions, usually occurring during the first 6 weeks of taking the drug in a small percent of people. The new drug label warns that those who use the drug and experience these side effects should immediately contact their health providers to discuss possibly stopping Intelence.

The side effects include severe skin reactions, including the life-threatening rash called Stevens-Johnson syndrome. Other hypersensitivity reactions include fever, general ill feeling, extreme tiredness, muscle or joint aches, blisters, oral lesions, eye inflammation, facial swelling and/or signs and symptoms of liver problems.




This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art55658.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.